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Objective: The aims of this study were to obtain cross-sectional data on capillaroscopy in an international
multi-center cohort of Systemic Sclerosis (SSc) and to investigate the frequency of the capillaroscopic patterns
and their disease-phenotype associations.
Methods: Data collected between June 2004 and October 2011 in the EULAR Scleroderma Trials and Research
(EUSTAR) registry were examined. Patients' proﬁles based on clinical and laboratory data were obtained by, Istituto Gaetano Pini, Department of Clinical & Community Sciences, University of Milano, Piazza Cardinal Ferrari 1, 20122
egnoli).
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123F. Ingegnoli et al. / Microvascular Research 89 (2013) 122–128cluster analysis and the association between proﬁles and capillaroscopywas investigated bymultinomial logistic
regression.
Results: 62 of the 110 EUSTAR centers entered data on capillaroscopy in the EUSTAR database. 376 of the 2754
patients (13.65%) were classiﬁed as scleroderma pattern absent, but non-speciﬁc capillary abnormalities were
noted in 55.48% of the cases. Fourmajor patients' proﬁles were identiﬁed characterized by a progressive severity
for skin involvement, aswell as an increased number of systemic manifestations. The “early” and “active” sclero-
derma patterns were generally observed in patients withmild/moderate skin involvement and a low number of
disease manifestations, while the “late” scleroderma pattern was found more frequently in the more severe
forms of the disease.
Conclusion: These data indicate the importance of capillaroscopy in SSc management and that capillaroscopic
patterns are directly related to the extent of organ involvement.© 2013 Elsevier Inc. All rights reserved.Introduction
Systemic sclerosis (SSc) is a severe connective tissue disease in
which vascular dysfunction, tissue ﬁbrosis and immune dysregulation
are key events. SSc has a heterogeneous clinical presentation, but skin
and vascular changes are the hallmark of the disease (Geyer andMuller-
Ladner, 2011; Herrick, 2012). Pathologicalmicrovascular ﬁndings in SSc
document a signiﬁcant loss of the peripheral vascular network, with
loss of capillaries, deﬁcient vascular repair and the absence of new
vessel growth, and subsequent tissue ischemia and ﬁbrosis (Brown
and O'Leary, 1925; Herrick and Cutolo, 2010; Kuwana et al., 2004).
The sequence of these alterations in the microcirculation can be
observed using a reliable, rapid, non-invasive examination such as
nailfold capillaroscopy, which can be regarded as the most valuable
technique for assisting the early diagnosis of SSc and monitoring the
evolution of microangiopathy in overt SSc (Avouac et al., 2011; Cutolo
et al., 2010). Capillaroscopy is a powerful in vivo tool not only in screen-
ing patients with Raynaud's phenomenon for underlying scleroderma
spectrum disorders (Ingegnoli et al., 2008, 2010; Nagy and Czirjak,
2004; Vayssairat et al., 1982), but also in detecting the progressivemicro-
vascular damage during the course of SSc (Herrick and Cutolo, 2010).
The distinctive and identiﬁable morphological nailfold changes
observed inpatientswith SSc have been extensively studied; they include
enlarged loops, giant capillaries, neovascularization, capillary loss, and
disrupted architecture of the nailfold microvascular network (Bukhari
et al., 1996; Herrick and Cutolo, 2010; Herrick et al., 2010; Maricq and
LeRoy, 1973;Maricq et al., 1980, 1983). Thesemicrovascular scleroderma
speciﬁc capillaroscopy abnormalities were initially described by Maricq
(Maricq et al., 1980, 1983) and called “scleroderma patterns”; subse-
quently they were classiﬁed into 3 different patterns, which include an
“early” pattern (i.e. few enlarged/giant capillaries, few capillary hemor-
rhages, no evident loss of capillaries), an “active” pattern (i.e. frequent
giant capillaries, frequent capillary hemorrhages, mild disorganization
of the capillary network), and a “late” pattern (i.e. irregular enlargement
of the capillaries, few or absent giant capillaries, hemorrhages, and exten-
sive avascular areas) (Cutolo et al., 2000).
In order to clarify with further aspects the reported associations
between nailfold capillary abnormalities and clinical and/or laboratory
features (Bredemeier et al., 2004; Caramaschi et al., 2007; Chen et al.,
1984; Cutolo et al., 2004; Hofstee et al., 2009; Lovy et al., 1985; Smith
et al., 2012; Sulli et al., 2012) it was decided to evaluate a large multi-
national group of patients with SSc such as the international multi-
center cohort of the EULAR Scleroderma Trials And Research
(EUSTAR) registry.
Therefore, the steps of this cross-sectional study were:
- To ascertain the use of capillaroscopy in everyday practice in the
EUSTAR centers. Due to the fact that data on capillaroscopy were
not mandatory points in the database, a lot of missing data on this
topic were present. Therefore, EUSTAR centers were invited to give
additional information by a short survey for assessing whether and
how capillaroscopy is performed.- To deﬁne a proper target population and to evaluate if the sample of
patients in the study was representative of the population. After
completing as much as possible the missing information, the target
population was identiﬁed with inclusion and exclusion criteria.
The representativity of the sample studied was evaluated com-
paring the characteristics of patients with and without informa-
tion on capillaroscopy.
- To determine the frequency of capillaroscopic patterns (i.e. sclero-
derma pattern vs non-scleroderma pattern) in adult SSc patients,
and to identify disease-phenotype associations. For this purpose
clinical and demographic characteristics of patients with and with-
out scleroderma pattern were compared.
- To examine the prevalence of the three different sclerodermapatterns
(i.e. early, active or late) and to better characterize these patterns in
terms of their association with disease measurements, clinical and
laboratory features.With this aim clinical anddemographic character-
istics of patients with early, active or late scleroderma pattern were
compared.
- To evaluate jointly the association between clinical/laboratory infor-
mation and capillaroscopic patterns. For this purpose, ﬁrstly groups
(proﬁles) of patients which were homogeneous for their clinical/
laboratory characteristics were obtained by cluster analysis; thus,
these patients' proﬁles were related with capillaroscopy data.Materials and methods
The EUSTAR database
This EUSTAR study on capillaroscopy is based on data collected
from the SSc patients entered in the EUSTAR registry. This database
was launched in June 2004 and documents a multi-national, prospective
and open SSc cohort. Participating medical centers have entered the
data of consecutive patients into a speciﬁc database, whichwas deﬁnitely
locked for this study inOctober 2011. The structure andminimal essential
dataset (MEDS) of the EUSTAR database have been previously described
(Tyndall et al., 2005; Walker et al., 2007). The MEDS was constructed
with the consensus of EUSTAR members, and includes demographic and
laboratory data, disease duration and organ involvement.
To guarantee the quality and the standardization of the clinical
and capillaroscopic assessments, EUSTAR and EULAR regularly held
courses to coach, update and standardize the assessment of SSc
patients. In every course there is a coaching session speciﬁcally de-
voted to capillaroscopy. Moreover additional coaching materials
are available on the EUSTAR website.
As shown in Fig. 1, the data on capillaroscopy are assessed in the
following manner: a) scleroderma pattern as “present” or “absent”;
and b) in its presence, speciﬁcation of its type (i.e. early, active or late).
These 2 points are not mandatory. Capillaroscopy examination was per-
formed generally on eight digits (excluded thumbs) using the technical
equipment available in each EUSTAR center, ranging from video-
capillaroscope to dermatoscope with magniﬁcation from 20× to 200×.
Fig. 1. Items on capillaroscopy of the Minimal Essential Dataset (MEDS) in the EUSTAR registry (A). The data are assessed as scleroderma patter “absent” (B) or “present”; and in its
presence, speciﬁcation of its type: early (C), active (D) or late (E). Magniﬁcation 200×.
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previous studies on the agreement between capillaroscopic methods
(Anders et al., 2001;Wildt et al., 1999, 2012), and because data collected
in the EUSTAR registry are based on an overall capillaroscopic pattern
characterized only bymorphological capillary abnormalities easily iden-
tiﬁable with all the tools employed.
All of the patients included in the database gave their informed con-
sent, and the study was approved by the various institutional Ethics
Committees.
Study design
For the ﬁrst purpose of this study, EUSTAR centers were invited to ﬁll
out a speciﬁcally designedquestionnaire,which required them to give the
reason for any incomplete capillaroscopic information (i.e. capillaroscopy
not routinely assessed, performed only when speciﬁcally requested,
assessed but not recorded in the database, or recently introduced) and
to specify the instrument used (i.e. video-capillaroscope, microscope,
dermatoscope or other). To ensure security and conﬁdentiality, each par-
ticipant received a personal e-mail invitationwith individual access to an
attached standardized questionnaire; the same formwas also distributed
and collected during a EUSTAR meeting.
In the following parts of this study, eligible patients were adult SSc
of EUSTAR centers in which capillaroscopy exam was routinely per-
formed. Therefore, data from the EUSTAR database were analyzed
by excluding: a) patients with juvenile SSc (Zulian et al., 2007) and,
b) EUSTAR centers without any data on capillaroscopy or with less
than 15% of capillaroscopic reports or with less than 5 capillaroscopies
were excluded.
The MEDS data closest to the date of capillaroscopy were used in
the analysis. From the collected MEDS data is not possible to describe
the capillary abnormalities when scleroderma pattern is absent. In itsabsence, EUSTAR participants were invited to ﬁll out a standardized
form, which required them to specify the capillary pattern (normal
or capillary abnormalities other than a scleroderma pattern).
For all patients with SSc, disease activity was assessed using the ac-
tivity indices described by the European Scleroderma Study Group
(Valentini et al., 2001, 2003). According to these criteria, SSc was con-
sidered active if the overall score was ≥3. Disease stages were deﬁned
as: early limited cutaneous (lc)-SSc (disease duration b5 years), inter-
mediate/late lcSSc (disease duration≥5 years), early diffuse cutaneous
(dc)-SSc (disease duration b3 years), and intermediate/late dcSSc
(disease duration ≥3 years) (Medsger and Steen, 1996). Modiﬁed
Rodnan skin score (mRSS) has been classiﬁed as: normal = 0, mild
between 1 and 14, moderate between 15 and 29, severe between
30 and 39, endstage >40 (Medsger et al., 2003).
Statistical analysis
The Chi Squared Test with Bonferroni correction for multiple com-
parisons was used to investigate differences in distribution of disease
manifestation between: patients included, with andwithout scleroderma
pattern; and patients with speciﬁed scleroderma pattern: early, active
and late.
Aiming to identify patients' proﬁles based on clinical manifestations,
agglomerative hierarchical cluster analysis was performed. Clustering is
a technique that allows the classiﬁcation of patientswithin homogeneous
subsets (cluster), by the deﬁnition of a “distance” measure between
subjects on the basis of their characteristics. A subgroup of variables in-
cluding clinical manifestations such as esophageal, stomach, intestinal,
renal, Raynaud's phenomenon, active digital ulcers, scleredema, mRSS,
synovitis, contractures, tendon friction rubs (TFR), muscle weakness
and atrophy, heart conduction block, pericardial effusion, lung ﬁbrosis,
pulmonary arterial hypertension (PAH) and diffusing lung capacity of
Fig. 2. Flowchart of the study.
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antinuclear antibodies (ANA), anticentromere antibodies (ACA), and
antitopoisomerase I antibodies (Scl70) were considered. U1RNP and
RNA were excluded due to the large number of missing values.
In order to facilitate the calculation of the distance among subjects,
Multiple Correspondence Analysis (MCA) (Greenacre, 1993) was pre-
liminarily performed. MCA extracts relevant information from a large
amount of data by reducing a starting set of correlated variables into a
smaller set of uncorrelated ones (namely factor or axis), ordered on
the basis of the amount of data variability they explain. Each individual
can be represented by its coordinates on the newly identiﬁed factorial
axis; thus patients with similar coordinates' values share similar charac-
teristics. Disease subsets and capillaroscopy patterns were used as sup-
plementary passive variables (i.e. these variables did not contribute to
the identiﬁcation of the clusters among other variables).
The stability of cluster assignment (i.e. internal validation) was also
investigated. Resamplingmethodswere utilized to face this issue during
two steps separately; ﬁrstly to determine the number of clusters and
secondly to assess the reliability of each cluster by conditioning to a
ﬁxed number of clusters. Then the agreement (similarity) between
each clustering run on the perturbed data and the clustering on original
data set were assessed via the Jaccard's coefﬁcient (Hennig, 2007). In
both steps, 1500 bootstrap resamples with replacement were randomly
generated from the original data set.
Finally,multinomial logistic regression analysiswas used to evaluate
the association among the identiﬁed clusters and the capillaroscopy
patterns.
Statistical analysis was carried out using software R (R Development
Core Team, 2006), with FactoMineR and ca packages added.
Results
Use of nailfold capillaroscopy
A short survey was undertaken to collect information on
capillaroscopy and response rate was 33.6% (37 of 110 centers), of
whom 91.4% are European centers. In 18.9% (7 of 37) capillaroscopy
was not routinely assessed, whereas in the 67.6% (25 of 37) of cases
capillaroscopy was performed but data were not reported in the
EUSTAR database. In 10 of 37 (27.0%) centers, capillaroscopy technique
had been recently introduced and a videocapillaroscopic equipment
was available only in 26 of 37 (70.3%) centers, otherwise microscope
(24.3%) and dermatoscope (5.4%) were used.
SSc patients with scleroderma pattern vs SSc patients without
scleroderma pattern
Firstly, the impact of exclusion criteria and the impact ofmissingness
with regard to capillaroscopy data were evaluated. In Fig. 2 the main
steps for selecting patients are described. A total of 9034 patients from
110 centers were recorded in the EUSTAR database locked for this
study in October 2011. 5214 adult SSc patients within 62 out of 110
centers were eligible for the study. Among these, 1189 patients who
had at least one capillaroscopy examination reported in the database
and complete information on clinical/laboratory features were studied.
Characteristics of the study population are reported in Table 1.
There were no relevant clinical and demographic differences between
these groups.
Complete data on the presence or absence of a scleroderma pattern
were available for 2754 SSc patients, whose main characteristics are
shown in Table 2. The following characteristics were more frequently
observed in patients with scleroderma pattern: dcSSc, active disease,
digital ulcers, joint contractures, ANA and Scl-70 positive.
In 376 of 2754 (13.65%) patients the capillaroscopy pattern was
not classiﬁed as scleroderma pattern. A detailed description of these
capillaroscopy patterns was obtained in 256 of 376 (68.09%) of thecases. The capillaroscopy pattern was classiﬁed as normal in 70 of 256
(27.34%). However, non-speciﬁc capillary abnormalities were reported
in 142 of 256 (55.48%), and otherwise the capillaroscopy pattern was
not of clear interpretation because of the poor quality of images in 44
of 256 (17.18%). Non-speciﬁc capillary abnormalities were deﬁned as
enlarged and tortuous loops with hemorrhages. With regard to the
characteristics of SSc patients without scleroderma pattern, dcSSc
subtype, ANA positive, Scl-70 positive, digital ulcers and joint contrac-
tures were less frequent.
Scleroderma pattern “early” vs “active” vs “late” pattern
Data on the subtype of scleroderma pattern were available for
1870 out of 2754 patients. The disease characteristics of patients
with different scleroderma patterns are shown in Table 3. It can be
noted that patients with “late” scleroderma pattern are more frequently
dcSSc with Scl-70 positive. Moreover, regarding clinical manifestations,
an increased frequency of digital ulcers, and of lung, heart and musculo-
skeletal involvement is noted from patients with “early” pattern as com-
pared to those with “late” pattern.
The further step was the cluster analysis performed on a complete
case basis, including only the 1189 among 1870 patients, those with
complete information on clinical symptoms, disease manifestation
and autoantibodies proﬁle.
The ﬁrst three factorial axis generated by MCA analysis explained
near the 80% of the overall variability in the data and were used to
perform the subsequent cluster analysis on patient coordinates. The
cluster analysis suggests the presence of four major patients' proﬁles,
whose characteristics about the distribution of disease manifestations
are shown Table 4.
The ﬁrst cluster mainly refers to subjects without Raynaud's phe-
nomenon, with autoantibodies negative and without organ involve-
ment and without a capillaroscopic scleroderma pattern. The second
cluster mainly identiﬁes patients with lcSSc with normal/mild mRSS,
Table 1
Characteristics of the study population of the EUSTAR database up to October 2011.
EUSTAR centers (no. 110)
Included (no. 62) Excluded
(no. 48)
With data on
capillaroscopy
Without data on
capillaroscopy
No data on
capillaroscopy
No. of patients 2754 2460 3678
Female 2400 (87.15%) 2096 (85.20%) 3220 (87.54%)
Age, mean ± SD years 54.97 ± 13.6 56.16 ± 13.5 55 ± 13.5
Disease duration,
mean ± SD years
7.62 ± 7.38 8.26 ± 8.03 8.32 ± 8. 06
Cutaneous subtype, no. %
Limited 1622 (58.9%) 1377 (55.97%) 1982 (53.89%)
Diffuse 803 (29.15%) 841 (34.19%) 1159 (31.51%)
Other 328 (11.91%) 215 (8.74%) 492 (13.38%)
Not classiﬁed 1 (0.04%) 27 (1.1%) 45 (1.22%)
Raynaud's phen., no. % 2615 (97.15%) 2360 (97,00%) 3405 (92.57%)
Digital ulcers, no. % 934 (33.91%) 769 (31.26%) 1123 (30.53%)
Pulmonary ﬁbrosis, no. % 716 (30.08%) 946 (42.77%) 1117 (32.58%)
PAH, no. % 477 (17.32%) 583 (23.69%) 1020 (27.95%)
Muscle weakness, no. % 489 (18.07%) 625 (25.88%) 1020 (29.88%)
Joint contractures, no. % 711 (26.02%) 711 (29.49%) 1099 (30.06%)
Synovitis, no. % 370 (13.43%) 381 (15.48%) 570 (15.49%)
Tendon friction rubs, no. % 218 (7.75%) 208 (8.66%) 376 (10.36%)
Renal crisis, no. % 42 (1.52%) 51 (2.07%) 92 (2.50%)
Conduction blocks, no. % 310 (11.25%) 327 (13.29%) 266 (7.23%)
Positive ANA, no. % 2583 (94.79%) 2213 (92.29%) 3308 (92.09%)
Positive Scl-70, no. % 878 (32.88%) 765 (32.09%) 1121 (32.00%)
Positive ACA, no. % 1068 (39.77%) 794 (34.27%) 1222 (35.22%)
Active disease according
to European score, no. %
337
(1344 missing)
111
(2057 missing)
107
(3414 missing)
SD: standard deviation; PAH: pulmonary arterial hypertension; ANA: antinuclear
antibodies; Scl-70: antitopoisomerase-1 antibodies; ACA: anticentromere antibodies.
Table 2
Disease characteristics of systemic sclerosis patients with and without a scleroderma
pattern by nailfold capillaroscopy.
EUSTAR centers included (no. 62)
With data on capillaroscopy (no. 2754)
Without scleroderma
pattern
With scleroderma
pattern
p
No. of patients 376 2378 NS
Female 310 (82.45%) 2091 (87.93%) NS
Age, mean ± SD years 56.10 ± 13.4 54.81 ± 13.7 NS
Disease duration,
mean ± SD years
7.18 ± 7.24 7.69 ± 7.40 NS
Cutaneous subtype, no. % *
Limited 225 (59.84%) 1398 (58.79%)
Diffuse 74 (19.68%) 729 (30.66%)
Other 75 (19.95%) 250 (10.51%)
Not classiﬁed 2 (0.53%) 1 (0.04%)
Raynaud's phen., no. % 329 (92.20%) 2286 (97.69%) *
Digital ulcers, no. % 70 (18.61%) 864 (36.33%) *
Pulmonary ﬁbrosis, no. % 78 (24.74%) 638 (30.82%) NS
PAH, no. % 48 (14.20%) 429 (19.40%) NS
Muscle weakness, no. % 51 (13.56%) 438 (18.41%) NS
Joint contractures, no. % 52 (14.82%) 659 (27.71%) *
Synovitis, no. % 41 (10.90%) 329 (13.83%) NS
Tendon friction rubs, no. % 23 (6.11%) 195 (8.20%) NS
Renal crisis, no. % 7 (1.86%) 35 (1.47%) NS
Conduction blocks, no. % 43 (12.13%) 267 (11.83%) NS
Positive ANA, no. % 330 (89.76%) 2253 (95.55%) *
Positive Scl-70, no. % 91 (25.20%) 787 (34.09%) *
Positive ACA, no. % 140 (38.26%) 929 (39.76%) NS
Active disease according to
European score, no. %
23 (13.86%) 314 (25.22%) *
SD: standard deviation; PAH: pulmonary arterial hypertension; ANA: antinuclear
antibodies; Scl-70: antitopoisomerase-1 antibodies; ACA: anticentromere antibodies;
NS: not signiﬁcant; *: p b 0.05.
Table 3
Disease characteristics of patients with scleroderma pattern early, active or late by nailfold
capillaroscopy.
EUSTAR centers included (no. 62)
With scleroderma pattern (no. 1870)
Scleroderma
pattern early
Scleroderma
pattern active
Scleroderma
pattern late
p
No. of patients 494 778 598 NS
Female 454 (91.90%) 673 (86.5%) 522 (87.29%) NS
Age, mean ± SD years 53.53 ± 13.93 54.24 ± 13.44 56.62 ± 13.03 NS
Disease duration,
mean ± SD years
6.23 ± 6.47 7.48 ± 6.98 9.95 ± 8.08 NS
Cutaneous subtype, no. % *
Limited 307 (62.14%) 457 (58.74%) 288 (48.16%)
Diffuse 105 (21.26%) 222 (28.53%) 278 (46.49%)
Other 82 (16.60%) 98 (12.6%) 32 (5.35%)
Not classiﬁed 0 1 (0.13%) 0
Raynaud's phen., no. % 473 (96.75%) 761 (97.81%) 576 (96.32%) NS
Digital ulcers, no. % 121 (24.49%) 287 (36.88%) 292 (48.83%) *
Pulmonary ﬁbrosis, no. % 120 (27.03%) 221 (31.13%) 227 (43.29%) *
PAH, no. % 51 (14.41%) 151 (20.60%) 152 (27.94%) *
Muscle weakness, no. % 78 (17.58%) 137 (17.60%) 157 (26.25%) *
Joint contractures, no. % 74 (14.98%) 214 (27.50%) 276 (46.39%) *
Synovitis, no. % 51 (10.32%) 118 (15.16%) 109 (18.22%) *
Tendon friction rubs, no. % 18 (3.64%) 76 (9.77%) 83 (13.88%) *
Renal crisis, no. % 2 (0.40%) 10 (1.29%) 13 (2.17%) NS
Conduction blocks, no. % 37 (7.99%) 96 (13.34%) 97 (17.41%) *
Positive ANA, no. % 472 (96.74%) 747 (96.61%) 555 (94.07%) NS
Positive Scl-70, no. % 136 (28.53%) 254 (32.64%) 275 (47.33%) *
Positive ACA, no. % 219 (45.15%) 332 (43.37%) 160 (27.56%) *
Active disease according
to European score, no. %
43 (13.87%) 114 (23.65%) 130 (37.14%) *
PAH: pulmonary arterial hypertension; ANA: antinuclear antibodies; Scl-70:
antitopoisomerase-1 antibodies; ACA: anticentromere antibodies; NS: not signiﬁcant;
*: p b 0.05.
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with no active digital ulcers. The third cluster is mainly characterized
by patients with dcSSc or intermediate/late lcSSc with moderate mRSS,
with ANA positive and organ involvement (i.e. joint contractures, TFR,
synovitis and lung ﬁbrosis). The forth cluster mainly refers to patients
with dcSSc with more severe mRSS and with multiple organ involve-
ment (i.e. gastro/intestinal, muscle, renal and heart involvement, joint
contractures and TFR). The scleroderma pattern was mainly present in
the second, third and fourth group, whereas patients with absent sclero-
derma patternweremainly classiﬁed in cluster 1 (24.41%) and in cluster
2 (48.03%).
The internal validation process identiﬁed only two clusters. Cluster A
(that included cluster 1, 2 andpart of cluster 3)was characterized by less
severe clinical manifestations, while cluster B (that included cluster 4
and part of cluster 3) grouped patients with more severe disease and
with a heterogeneous pattern of clinical symptoms.
The strength of association between the above-mentioned four
clusters of patients' proﬁles and the scleroderma patterns were also
studied. The odds of the scleroderma pattern “active” or “late” vs the
“early” pattern in each cluster were evaluated. The “active” pattern
was more likely to be observed in clusters three and four with respect
to cluster 1 (OR 1.7, 95% CI 0.89–2.27 and OR 4.07, 95% CI 1.95–8.49
respectively); as much as the “late” pattern was more likely to be
reported in clusters three and four (OR 2.7, 95% CI 1.58–4.79 and OR
6.92, 95% CI 3.26–14.69) with respect to cluster 1.Discussion
In the context of a constant chase for identifying a useful non-
invasive tool to monitor SSc, the results of this large study on
capillaroscopy add important information concerning the actual role
of capillaroscopy.
Table 4
Disease characteristics of patients in the four major patients' proﬁles obtained from
systemic sclerosis in the EUSTAR database by cluster analysis.
Cluster 1 Cluster 2 Cluster 3 Cluster 4
No. of patients 168 548 318 155
Raynaud's phen., no. % 147 (87.5%) 546 (99.6%) 315 (99.05%) 154 (99.35%)
Active digital ulcers, no. % 4 (2.4%) 46 (8.4%) 71 (22.3%) 59 (38.06%)
Scleredema, no. % 35 (20.8%) 237 (43.2%) 152 (47.8%) 60 (38.7%)
mRSS, no. %
□ Normal
□ Mild
□ Moderate
□ Severe
□ Endstage
18 (10.7%)
132 (78.6%)
13 (7.7%)
5 (3%)
0
87 (15.9%)
438 (79.9%)
23 (4.2%)
0
0
3 (0.9%)
208 (65.4%)
104 (32.8%)
3 (0.9%)
0
5 (3.2%)
69 (44.5%)
61 (39.4%)
16 (10.3%)
4 (2.6%)
Esophageal involvement,
no. %
68 (40.5%) 339 (61.9%) 203 (63.8%) 138 (89.03%)
Stomach involvement,
no. %
8 (4.8%) 99 (18.06%) 46 (14.5%) 113 (72.9%)
Intestinal involvement,
no. %
23 (13.7%) 134 (24.4%) 29 (9.1%) 83 (53.5%)
Pulmonary ﬁbrosis, no. % 63 (37.5%) 40 (7.3%) 175 (55%) 91 (58.7%)
DLCO b70 no. % 111 (66.1%) 275 (50.2%) 278 (87.4%) 134 (86.45%)
PAH, no. % 26 (15.5%) 77 (14.05%) 101 (31.8%) 59 (38.06%)
Muscle weakness, no. % 25 (14.9%) 55 (10%) 50 (15.7%) 108 (69.7%)
Muscle atrophy, no. % 6 (3.6%) 5 (0.9%) 4 (1.25%) 81 (52.25%)
Joint contractures, no. % 41 (24.4%) 50 (9.1%) 148 (46.5%) 112 (72.25%)
Synovitis, no. % 18 (10.7%) 27 (4.9%) 82 (25.8%) 48 (31%)
Tendon friction rubs,
no. %
3 (1.8%) 5 (0.9%) 51 (16%) 46 (29.7%)
Renal crisis, no. % 4 (2.4%) 1 (0.2%) 0 10 (6.45%)
Pericardial effusion 4 (2.4%) 15 (2.8%) 31 (9.7%) 20 (12.9%)
Conduction blocks, no. % 11 (6.5%) 43 (7.8%) 46 (14.5%) 41 (26.45%)
Positive ANA, no. % 119 (70.8%) 548 (100%) 318 (100%) 152 (98%)
Positive Scl-70, no. % 7 (4.2%) 101 (18.4%) 240 (75.5%) 83 (53.5%)
Positive ACA, no. % 2 (1.2%) 378 (69%) 33 (10.4%) 35 (22.6%)
mRSS: modiﬁed Rodnan skin score; DLCO: diffusing lung capacity of the lung for carbon
monoxide; PAH: pulmonary arterial hypertension; ANA: antinuclear antibodies; Scl-70:
antitopoisomerase-1 antibodies; ACA: anticentromere antibodies.
127F. Ingegnoli et al. / Microvascular Research 89 (2013) 122–128The ﬁrst part of this study aimed to depict the use of capillaroscopy in
clinical practice. A lowadherence to the surveywas observed, but the col-
lected data conﬁrm that this technique is particularly used in European
countries. This diagnostic tool was only recently introduced in clinical
practice in 27% of centers, thus suggesting an increased interest
in capillaroscopy. It is a matter of fact that different devices
(e.g. videocapillaroscope, microscope, or dermatocope) are used to per-
form the exam. The variability in the way capillaroscopy is employed
and performed by clinicians could be related to different aspects of
everyday practice such as: health-care system access and utilization,
reimbursement policy and physician experience.
In this study the potential heterogeneity related to the analysis of
capillaroscopic images has been overcome by continuous EUSTAR/
EULAR effort to coach, update and standardize the assessment of SSc
patients.
In addition, the data collected in the EUSTAR registry are based on an
overall capillaroscopic pattern characterized only by morphological
capillary abnormalities easily identiﬁablewith all the tools as previously
demonstrated (Anders et al., 2001; Baron et al., 2007; Beltran et al.,
2007; Bukhari et al., 2000; Hudson et al., 2010;Wildt et al., 1999, 2012).
In the EUSTAR registry, capillaroscopy scleroderma pattern was ob-
served in more than 86% of SSc subjects, while in the other patients
capillaroscopy patternwas characterized by non-speciﬁc capillary abnor-
malities other than scleroderma pattern, and in a minority of patients
capillaroscopy was within the normal range. Patients within this group
generally do not have organ involvement, Raynaud's phenomenon and
also have negative antibodies; these data may suggest that even though
they are classiﬁed as SSc probably they do not have an overt disease,
and that non-speciﬁc capillary abnormalities may precede a full-blown
scleroderma pattern. This subgroup has been recently studied in depth
by other EUSTAR members (Schneeberger et al., 2013).On the other hand, the patients' proﬁles identiﬁed by the cluster
analysis were in a progressive order of severity for skin as well as
organ involvement. In patients with overt SSc, capillaroscopy sclero-
derma pattern is almost always present. Particularly, in the initial
stages of the disease or when the organ involvement is less severe
the “early” (or “active”) scleroderma patterns may be observed, while
in themore severe forms of the disease the capillaroscopic scleroderma
pattern “late” becomes more frequent. These results advocate the im-
portant role of capillaroscopy images as a mirror of internal organ in-
volvement progression.
In fact, it has long been known that the damaged capillary network
in SSc results in micro-vessel abnormalities that can worsen during
disease progression (Caramaschi et al., 2007; Cutolo et al., 2004).
These observations conﬁrm the results of a recent longitudinal study
that reported a dynamic transition of microvascular damage through
different capillaroscopy patterns in nearly 50% of SSc patients (Smith
et al., 2012; Sulli et al., 2012).
It has been argued that widespread use of appropriately developed
capillaroscopy technique can be of a great value for an early diagnosis
of SSc and inmonitoring the disease course, even if themajority of pub-
lisheddata regarding capillaroscopy are derived from limitednumber of
patients. This study can be considered a ﬁrst effort to ascertain the use
of capillaroscopy because this data are extrapolated from the EUSTAR
registry that is conducted in a multicenter real world setting.
Limitations of this study include themissing information concerning
some clinical, laboratory and particularly full capillaroscopy data. On
the one hand, these latter information were often missed in the data-
base since were not mandatory, and it was difﬁcult to obtain new data
which were previously not recorded. However patients included and/
or excluded from the analysis had similar characteristics thus a relevant
selection bias was not suspected. Due to the fact that capillaroscopy is
an operator dependent method, the inter-individual and intra-center
variability might also inﬂuence the results. This potential confounder
may be reduced by the inclusion of a large number of centers contribut-
ing to MEDS. Even if a consistent number of patients needed to be ex-
cluded from the analysis, this is the largest multicenter international
cohort of SSc patients in which capillaroscopy was studied.
In conclusion, capillaroscopy should bepart of the screening andmon-
itoring process of SSc, because it is directly related to the extent of organ
involvement. These data also indicate the large use of capillaroscopy in-
ternationally and that the variability with which a seemingly straightfor-
ward technique such as capillaroscopy is used in everyday practice
(Cutolo et al., 2012; De Angelis et al., 2009).
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